Cipher Pharmaceuticals - CPH Competitors

Cipher Pharmaceuticals (TSE:CPH) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.

Is CPH or RX more profitable?

Cipher Pharmaceuticals has a net margin of 128.83% compared to BioSyent's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 51.73% beat BioSyent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	128.83%	51.73%	11.01%
BioSyent	N/A	19.38%	13.03%

Does the media prefer CPH or RX?

In the previous week, BioSyent had 10 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 10 mentions for BioSyent and 0 mentions for Cipher Pharmaceuticals. BioSyent's average media sentiment score of 0.58 beat Cipher Pharmaceuticals' score of 0.00 indicating that BioSyent is being referred to more favorably in the news media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
BioSyent	Positive

Which has more volatility and risk, CPH or RX?

Cipher Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, BioSyent has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Does the MarketBeat Community believe in CPH or RX?

Cipher Pharmaceuticals received 82 more outperform votes than BioSyent when rated by MarketBeat users. However, 66.20% of users gave BioSyent an outperform vote while only 62.41% of users gave Cipher Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Cipher Pharmaceuticals	Outperform Votes 176 62.41%	Underperform Votes 106 37.59%
BioSyent	Outperform Votes 94 66.20%	Underperform Votes 48 33.80%

Do analysts recommend CPH or RX?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
BioSyent	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of CPH or RX?

0.2% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.3% of BioSyent shares are owned by institutional investors. 42.7% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 40.6% of BioSyent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, CPH or RX?

Cipher Pharmaceuticals has higher earnings, but lower revenue than BioSyent. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$20.68 million	4.03	C$26.64 million	C$0.46	7.22
BioSyent	C$27.68 million	3.28	C$6.14 million	C$0.49	15.31

Summary

Cipher Pharmaceuticals and BioSyent tied by winning 8 of the 16 factors compared between the two stocks.